Patents by Inventor Mark Dockrell

Mark Dockrell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEPHROPATHY BIOMARKER
    Publication number: 20170016914
    Abstract: The invention relates to a biomarker useful for the diagnosis of kidney disease and for determining patients whose disease severity level is likely to progress. The invention provides methods and products for determining the propensity for kidney disease progression.
    Type: Application
    Filed: March 6, 2015
    Publication date: January 19, 2017
    Inventors: Mark DOCKRELL, Nileshkumar SHAH
  • Antisense compounds targeting genes associated with fibronectin
    Patent number: 9487780
    Abstract: Provided are compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. Such hybridization results in modulation of splicing of the fibronectin transcript. Such compounds are used to treat one or more symptoms associated with fibrosis. Such compounds are used to treat one or more symptoms associated with renal fibrosis.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: November 8, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Frank Rigo, Mark Dockrell, Felicia Heidibrecht
  • ANTISENSE COMPOUNDS TARGETING GENES ASSOCIATED WITH FIBRONECTIN
    Publication number: 20150291955
    Abstract: Provided are compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. Such hybridization results in modulation of splicing of the fibronectin transcript. Such compounds are used to treat one or more symptoms associated with fibrosis. Such compounds are used to treat one or more symptoms associated with renal fibrosis.
    Type: Application
    Filed: June 3, 2013
    Publication date: October 15, 2015
    Applicants: SOUTH WEST THAMES INSTITUTE FOR RENAL RESEARCH, ISIS PHARMACEUTICALS, INC.
    Inventors: Susan M. Freier, Frank Rigo, Mark Dockrell, Felicia Heidibrecht